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Table 1
TNC
MeanSD (range)
CD34+
MeanSD (range)
Total cells Pre-
thaw
190.852.2 (70-359),
x107
8.85.1 (1.3-28), x106
Post-
thaw
171.353.9 (49.1-414.8),
x107
6.73.6 (1.3-21.2), x106
Per kg BW Pre-
thaw
2.70.8 (1.1-5.7),
x107
1.20.7 (0.2-4), x105
Post-
thaw
2.40.8 (0.9-6.9),
x107
0.90.5 (0.3-3.6), x105
Viability
(%)
42.613.1 (19-71.4) 9110.9 (47.8-100)
Table 2
TNC CD34+
Washed Diluted Washed Diluted
Difference (%)
between pre- and post-
thaw cell numbers
MeanSD (range)
16.110.2
(0.7-43.8)
9.56.4
(0.2-26.8)
22.614.6
(0.8-57.9)
2615.5
(0.2-76)
Mann-Whitney
score
0.0001 0.0621
Spearman’s rho 0.8661 0.9487 0.8578 0.8079
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285S260Cell dose is a major criterion for cord blood unit (CBU) se-
lection for allogeneic stem cell transplantation (allo-SCT).
The aim of this study was the characterization of CBU cellular
composition after thaw, and comparisonwith corresponding
values at cryopreservation as reported by cord blood (CB)
banks.
The study included 87 CBUs, that were thawed for infusion
in the context of single (n¼3) or dual-unit (n¼42) allo-SCT
in adults with hematologic malignancies, from 8/2006 to
6/2013. Upon thawing, the cryoprotective solution (DMSO
10%) was either removed by centrifugation/washing
(38 CBUs) or diluted in a less hypertonic solution of Dextran
40/Human Albumin 2.5% (49 CBUs). Total nucleated cells
(TNC) were measured with a hematology analyzer, while
enumeration of CD34+ stem cells was performed by single-
platform ﬂow cytometry, according to ISHAGE guidelines. In
49 units, TNC and CD34+ cell viability was evaluated by
addition of 7-AAD dye and sequential Boolean gating
strategy.
TNC counts after thawing were lower compared to their
values at freezing (Wilcoxon test, p <10-4), and the dif-
ference was more pronounced in the units that were
washed prior to infusion (Tables 1 and 2). Total cell
viability was low (mean value, 42.6%), but this was mainly
due to neutrophils. Regarding CD34+ cells, there was a
signiﬁcant difference between absolute counts at cryo-
preservation and at thaw (p<10-4). Despite reduction post-
thaw, the counts of both TNC and CD34+ cells did correlate
with the corresponding values at cryopreservation by
Spearman’s analysis. Of note, washing seemed slightly
advantageous in terms of CD34+ recovery (Tables 1 and 2).
CD34+ cells retained high viability after thaw, with 90% of
CBUs (44 out of 49 tested) demonstrating CD34+ viability
80%. Viability of <50% was noticed in only one CBU that
failed to engraft.
In conclusion, CB cellular content and especially the CD34+
cell count is frequently shown to be inferior at thaw
compared to cryopreservation. This probably reﬂects both
the lack of standardization of CD34+ cell measurement and
the effect of thawing procedure. Therefore, CD34+ cell
viability may be a more meaningful marker for determining
CBU quality.GVH/GVL
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Introduction: The optimal management of patients with
steroid refractory acute GVHD (SR-GVHD) is not yet deﬁned.
We examined the clinical courses of patients with SR-GVHD
treated with Alemtuzumab.
Methods: SR-GVHD was deﬁned as progression with 3 days
of 2 mg/kg of steroids, incomplete response in 7 days or
inability to taper steroids by 14 days. Of 211 consecutive
hematopoietic cell transplantation (HCT) recipients between
April 2011 and May 2013, 34 (16%) recipients developed SR-
GVHD and received Alemtuzumab (30mg subcutaneously
every 14 days until progression or severe infectious com-
plications for a maximum of 5 doses. Overall responses (OR)
were evaluated by day 28 and 56 after administration of
Alemtuzumab (McMillan et al, 2002).
Results: Median time to onset of acute GVHD was 25 days
(range 7-127) post-HCT. All patients received systemic ste-
roids ﬁrst line and were deﬁned as SR-GVHD. Median time
from steroid initiation to Alemtuzumab therapy was 12 days
(range 5-46). A median of 3 doses was given (range 1-4).
Twenty seven patients (80%) were alive and evaluable for
response by day 28 with 48% OR in 13 patients (8 CR and 5
PR), while 14 (52%) did not respond by day 28. Twenty pa-
tients (60%) were alive and evaluable for response by day 56
among whom 45% OR was noted (8 CR and 1 PR). No addi-
tional responses were observed after day 28 if not responded
within the ﬁrst 2 doses.
Median overall survival (OS) was 125.5 days (range 74-
328). The group responding to Alemtuzumab by day 28
showed a longer duration of OS (median 156 days) compared
to the non-responders by day 28 (median 99 days; p¼0.03).
However, all but one patient died of infection (n¼10), GVHD
(n¼16), GVHD and infection (n¼6) or other (n¼1). Infectious
events were noted in all 34 patients, with 117 events
including bacterial (n¼65 in 33 patients), viral (n¼44 in 28
patients) and fungal infections (n¼8 in 8 patients). Even in
the patients responding to Alemtuzumab by day 28, there
was one long-term survivor who is still alive at 310 days at
last follow-up
Conclusion: Response to Alemtuzumab seems to be an in-
dicator for prolonged OS duration in patients with SR-GVHD
although an improvement of 57 days is of questionable
clinical signiﬁcance given the morbidity associated with this
therapy. However, Alemtuzumab therapy does not improve
OS primarily because of high rate of infectious complication.
Better supportive care is needed to improve outcome from
infections after Alemtuzumab therapy for SR-GVHD.
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Table 3
Correlation between involvement of different parts of gastrointestinal tract
e colon/ileum biopsies versus stomach biopsies
Colon/Ileum
Biopsy Positive
Colon/Ileum
Biopsy Negative
Total
Stomach biopsy e
Positive
9 14 23 (85.2)
Stomach biopsy e
Negative
1 3 4 (14.8)
Total 10 (37) 17 (63) 27 (100)
p-value ¼ 0.001
(Mc Nemar test)
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Introduction: Graft-versus-host disease (GvHD) is a major
cause of mortality in allogeneic stem cell transplantation
(ASCT). This study assessed the distribution and concordance
of GvHD in upper and lower gastrointestinal (GI) biopsies
and its correlation with CMV infection and extra-intestinal
manifestations of GvHD.
Methods: We performed a review of records from patients
that had undergone ASCT from 2005 to 2013 in our institu-
tion and had GI GvHD diagnosis by histological samples from
upper and/or lower endoscopy. We also evaluate presence of
extra-intestinal manifestations of GvHD at the time of biopsy
and CMV infection on histological and blood samples.
Results: One hundred and eighty nine patients had per-
formed ASCT during this period. Twenty eight patients
(14.8%) had upper and/or lower acute GvHD diagnosis
conﬁrmed by biopsy. Extra-intestinal manifestation of GVHD
was: skin in 19 (67.9%) and liver in 6 (21.4%) patients. Five
(17.9%) had the 3 organ involvement. The GI GvHD staging
was: I in 7 (25%), II in 4 (14.3%), III in 9 (32.1%) and IV in 8
(28.6%) patients.
The frequency and correlation between involvement of
different parts of GI-GVHD are presented in Tables 1, 2 and 3.
Nine (32.1%) had a positive blood sample for CMV and 5
(17.9%) had a histological sample (one in stomach, 3 in colon
and one in rectum). Only one patient had both positive
samples. There is no association between GI-GVHD staging
and CMV infection on blood (p¼0.885) and on biopsy (p¼
0.859).Table 1
Correlation between involvement of different parts of gastrointestinal
tract e rectal biopsy versus colon/ileum biopsies
Colon/Ileum Biopsy
Positive
Colon/Ileum
Biopsy Negative
Total
Rectal biopsy e
Positive
16 7 23 (85.2)
Rectal biopsy e
Negative
2 2 4 (14.8)
Total 18 (66.7) 9 (33.3) 27 (100)
p-value ¼ 0.180
(Mc Nemar test)
Table 2
Correlation between involvement of different parts of gastrointestinal tract
e rectal biopsy versus stomach biopsies
Stomach biopsy e
Positive
Stomach biopsy e
Negative
Total
Rectal biopsy e
Positive
8 2 10 (37)
Rectal biopsy e
Negative
10 7 17 (63)
Total 18 (66.7) 9 (33.3) 27 (100)
p-value ¼ 0.039
(Mc Nemar test)The median follow up was 7.2 (1.8-90.6) month. Overall
survival was 40% in 60 months and patients with stage IV
GVHD had a less survival ( P¼ 0.004).
Conclusion: Because sigmoid tract was the most frequent
site of lower GI-GVHD involvement and only in 7.4% of cases
failed to identify this disease, a retosigmoidoscopymay be an
effective procedure for GI-GVHD diagnosis. However, CMV
infection may be underdiagnosed with this approach.405
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Introduction: Autologous graft versus host disease
(autoGVHD) is a recently recognized, rare transplant
complication with signiﬁcant morbidity and mortality.
Pathogenesis and risk factors for autoGVHD are poorly un-
derstood. We hypothesized that patients with multiple
myeloma might be predisposed to autoGVHD through dis-
regulation of immune response resulting from their treat-
ment with immunomodulatory agents (IMiDs) and
chemotherapeutic mobilization regimens.
Patients and Methods: We identiﬁed 8 patients with
multiple myeloma treated between 2005- 2013 with biopsy-
proven autoGVHD after transplant. We identiﬁed 2 non-
autoGVHD controls per autoGVHD patient matched by the
time of hematopoietic progenitor cell (HPC) collection
(within 15 days). Reference samples from HPC products of
autoGVHD, non-autoGVHD myeloma patients, and 7 healthy
controls were thawed and examined for cell surface marker
expression of CD3, CD4, CD8, CD25, and CD56 and intracel-
lular expression of FoxP3 by multicolor ﬂow cytometry. In-
formation on the following variables was collected: number
of transplants prior to developing autoGVHD, mobilization
regimens, exposure to a proteosome inhibitor, bortezomib,
and IMiDs (thalidomide, lenalidomide and pomalidomide),
and human leukocyte class I antigens (HLA A and B).
Results: Myeloma patients with and without autoGVHD
werewell matched for age (60 5.3 and 62.17.8 years) and
sex (50% and 43.8% male). Regulatory T-cells were decreased,
but not signiﬁcantly, in patients with autoGVHD (1.6  1.4%)
compared to non-autoGVHD patients (2.1  1.7%).There was
no difference in the NK cell population in the 2 groups. CD3+
cell percentage was signiﬁcantly lower in autoGVHD (46.6 
12.4%) than the non-autoGVHD patients (59.1  14.4%, p ¼
0.047). On subset analysis of CD3+ cells, CD8+ cells were
found to be signiﬁcantly lower in patients with autoGVHD
